Serum cystatin C level is a good prognostic marker in patients with cirrhotic ascites and normal serum creatinine levels

Liver International

Volumn 29, Issue 10, 2009, Pages 1521-1527

  Seo, Yeon Seok ^a   Jung, Eun Suk ^a   An, Hyonggin ^a   Kim, Jeong Han ^a   Jung, Young Kul ^a   Kim, Ji Hoon ^a   Yim, Hyung Joon ^a   Yeon, Jong Eun ^a   Byun, Kwan Soo ^a   Kim, Chang Duck ^a   Ryu, Ho Sang ^a   Um, Soon Ho ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Ascites; Creatinine; Cystatin C; Liver cirrhosis; Renal dysfunction

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYSTATIN C;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; ASCITES; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATORENAL SYNDROME; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHELOMETRY; PROGNOSIS; SURVIVAL RATE; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; BIOLOGICAL MARKERS; CREATININE; CYSTATIN C; FEMALE; GLOMERULAR FILTRATION RATE; HEPATORENAL SYNDROME; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 73449108407     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02105.x     Document Type: Article

References (34)

1. Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology 2008; 48: 2064-77.
2. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003; 38(Suppl. 1): S69-89.
3. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.
4. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
5. Cholongitas E, Shusang V, Marelli L, et al. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 2007; 26: 969-78.
6. Arroyo V, Fernandez J, Gines P. Pathogenesis and treatment of hepatorenal syndrome. Semin Liver Dis 2008; 28: 81-95.
7. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particleenhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40: 1921-6.
8. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312-8.
9. Randers E, Erlandsen E.J. Serum cystatin C as an endogenous marker of the renal function - a review. Clin Chem Lab Med 1999; 37: 389-95.
10. Sjostrom P, Tidman M, Jones I. Determination of the production rate and non-renal clearance of cystatin C and estimation of the glomerular filtration rate from the serum concentration of cystatin C in humans. Scand J Clin Lab Invest 2005; 65: 111-24.
11. Massey D. Commentary: clinical diagnostic use of cystatin C. J Clin Lab Anal 2004; 18: 55-60.
12. Demirtas S, Bozbas A, Akbay A, Yavuz Y, Karaca L. Diagnostic value of serum cystatin C for evaluation of hepatorenal syndrome. Clin Chim Acta 2001; 311: 81-9.
13. Gerbes AL, Gulberg V, Bilzer M, Vogeser M. Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 2002; 50: 106-10.
14. Larsen K. Creatinine assay by a reaction-kinetic principle. Clin Chim Acta 1972; 41: 209-17.
15. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
16. Wiesner R, Edwards E, Freeman R, et al. Model for endstage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
17. Cockcroft DW, Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
19. Hanley JA, McNeil B.J. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.
20. Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.
21. Llach J, Gines P, Arroyo V, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94: 482-7.
22. Tage-Jensen U, Henriksen JH, Christensen E, et al. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 1988; 6: 350-8.
23. Fernandez-Esparrach G, Sanchez-Fueyo A, Gines P, et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34: 46-52.
24. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-71.
25. Longheval G, Vereerstraeten P, Thiry P, et al. Predictive models of short- and long-term survival in patients with nonbiliary cirrhosis. Liver Transpl 2003; 9: 260-7.
26. Papadakis MA, Arieff A.I. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. Am J Med 1987; 82: 945-52.
27. Woitas RP, Stoffel-Wagner B, Flommersfeld S, et al. Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000; 46: 712-5.
28. Randers E, Ivarsen P, Erlandsen EJ, et al. Plasma cystatin C as a marker of renal function in patients with liver cirrhosis. Scand J Clin Lab Invest 2002; 62: 129-34.
29. Berenguer-Pina JJ, Noguera J, Canizares F, et al. Cystatin C: a marker of glomerular filtration rate in liver transplantation. Transplant Proc 2002; 34: 268-9.
30. Terg R, Gadano A, Cartier M, et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009; 29: 415-9.
31. Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005; 41: 32-9.
32. Londono MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56: 1283-90.
33. Huo TI, Lee SD, Lin H.C. Selecting an optimal prognostic system for liver cirrhosis: the model for end-stage liver disease and beyond. Liver Int 2008; 28: 606-13.
34. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology 2006; 44: 1535-42.